Market Cap 8.61B
Revenue (ttm) 7.34B
Net Income (ttm) 710.48M
EPS (ttm) N/A
PE Ratio 12.42
Forward PE 11.36
Profit Margin 9.67%
Debt to Equity Ratio 1.73
Volume 1,708,100
Avg Vol 3,330,326
Day's Range N/A - N/A
Shares Out 206.55M
Stochastic %K 78%
Beta 1.52
Analysts Sell
Price Target $53.20

Company Profile

Jefferies Financial Group Inc. operates as an investment banking and capital markets firm in the Americas, Europe, the Middle East, and the Asia-Pacific. It operates in two segments, Investment Banking and Capital Markets, and Asset Management. The company provides investment banking and advisory services for mergers or acquisitions, debt financing, restructurings, and private capital advisory transactions; underwriting and placement services related to corporate debt, municipal debt, mortgage-b...

Industry: Capital Markets
Sector: Financial Services
Phone: 212 284 2300
Address:
520 Madison Avenue, 10th Floor, New York, United States
Estimize
Estimize Apr. 2 at 8:00 PM
Wall St is expecting 0.98 EPS for $JEF Q2 [Reporting 07/01 AMC] http://www.estimize.com/intro/jef?chart=historical&metric_name=eps&utm_cont
0 · Reply
chriswong
chriswong Apr. 1 at 10:30 PM
$JEF I like the stock.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 31 at 3:06 PM
$JEF RSI: 59.56, MACD: -2.4152 Vol: 2.21, MA20: 39.23, MA50: 49.19 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Ro_Patel
Ro_Patel Mar. 31 at 2:32 PM
$LLY to acquire UK-based $CNTA in a deal worth up to $7.8B - to strengthen its neuroscience pipeline & expand into sleep medicine. Lilly will purchase all Centessa shares, including ADRs, for $38/share + up to an additional $9/share in contingent payments based on FDA approval milestones for Centessa's lead investigational candidate for certain neurological disorders The cash consideration, which represents a premium of about +41% to the 30-day VWAP of Centessa's ADS as of Monday, reflects an equity value of roughly $6.3B w/ the contingent payments represent an additional value of $1.5B Centessa is currently developing a pipeline of orexin receptor 2 agonists to treat excessive daytime sleepiness & disorders of impaired wakefulness. The company's lead investigational candidate, cleminorexton, has been evaluated in a phase 2a clinical trial for narcolepsy types 1 & 2 and idiopathic hypersomnia. Fin advisor for LLY was $MS & for Centessa $JEF
0 · Reply
RunnerSignals
RunnerSignals Mar. 30 at 8:31 PM
$CCL $LYV $NFLX $BP $JEF Upgrades today in the Buzz https://stocksrunner.com/news/2026-03-30-top-stock-upgrades-today-in-the-buzz
0 · Reply
Redw00d101
Redw00d101 Mar. 30 at 8:04 PM
$JEF don't get stuck in this
0 · Reply
CoolKennedy
CoolKennedy Mar. 30 at 6:47 PM
$JEF what's grooving
0 · Reply
erevnon
erevnon Mar. 26 at 4:00 PM
Goldman Sachs maintains Jefferies Financial $JEF at Buy and lowers the price target from $54 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
briefingcom
briefingcom Mar. 26 at 3:38 PM
$JEF: The transition story is intact, but not clean. Jefferies is gaining traction in investment banking, yet legacy issues continue to weigh on earnings visibility. See the full analysis: https://briefing.com/story-stocks/archive/2026/3/26/jefferies-posts-record-investment-banking-revenue-but-noncash-charges-muddy-profitability-(jef)?utm_campaign=storystocks&utm_medium=social&utm_source=st&utm_content=link $GS $MS #earnings #financialservices #capitalmarkets #investmentbanking
0 · Reply
Knot2
Knot2 Mar. 26 at 2:30 PM
$JEF don’t like the company but like the stock…keep accumulating
0 · Reply
Latest News on JEF
Jefferies Stock Falls. Private Credit Problems Hit Earnings.

Mar 26, 2026, 8:16 AM EDT - 9 days ago

Jefferies Stock Falls. Private Credit Problems Hit Earnings.


Jefferies Announces First Quarter 2026 Financial Results

Mar 25, 2026, 4:15 PM EDT - 10 days ago

Jefferies Announces First Quarter 2026 Financial Results


Jefferies Jumps on Report of Potential SMFG Takeover

Mar 24, 2026, 10:23 AM EDT - 11 days ago

Jefferies Jumps on Report of Potential SMFG Takeover

SMFG


Jefferies stock jumps on SMFG takeover report

Mar 24, 2026, 10:20 AM EDT - 11 days ago

Jefferies stock jumps on SMFG takeover report

SMFG


Jefferies Shares Spike Amid Buyout Talk From Japanese Lender

Mar 24, 2026, 9:54 AM EDT - 11 days ago

Jefferies Shares Spike Amid Buyout Talk From Japanese Lender

SMFG


Jefferies: Credit Concerns Overshadow Discounted Valuation

Mar 20, 2026, 4:47 PM EDT - 15 days ago

Jefferies: Credit Concerns Overshadow Discounted Valuation


Jefferies Comments on Western Alliance Bank Lawsuit

Mar 6, 2026, 8:26 AM EST - 4 weeks ago

Jefferies Comments on Western Alliance Bank Lawsuit


Jefferies Announces Fourth Quarter 2025 Financial Results

Jan 7, 2026, 4:15 PM EST - 3 months ago

Jefferies Announces Fourth Quarter 2025 Financial Results


Estimize
Estimize Apr. 2 at 8:00 PM
Wall St is expecting 0.98 EPS for $JEF Q2 [Reporting 07/01 AMC] http://www.estimize.com/intro/jef?chart=historical&metric_name=eps&utm_cont
0 · Reply
chriswong
chriswong Apr. 1 at 10:30 PM
$JEF I like the stock.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 31 at 3:06 PM
$JEF RSI: 59.56, MACD: -2.4152 Vol: 2.21, MA20: 39.23, MA50: 49.19 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Ro_Patel
Ro_Patel Mar. 31 at 2:32 PM
$LLY to acquire UK-based $CNTA in a deal worth up to $7.8B - to strengthen its neuroscience pipeline & expand into sleep medicine. Lilly will purchase all Centessa shares, including ADRs, for $38/share + up to an additional $9/share in contingent payments based on FDA approval milestones for Centessa's lead investigational candidate for certain neurological disorders The cash consideration, which represents a premium of about +41% to the 30-day VWAP of Centessa's ADS as of Monday, reflects an equity value of roughly $6.3B w/ the contingent payments represent an additional value of $1.5B Centessa is currently developing a pipeline of orexin receptor 2 agonists to treat excessive daytime sleepiness & disorders of impaired wakefulness. The company's lead investigational candidate, cleminorexton, has been evaluated in a phase 2a clinical trial for narcolepsy types 1 & 2 and idiopathic hypersomnia. Fin advisor for LLY was $MS & for Centessa $JEF
0 · Reply
RunnerSignals
RunnerSignals Mar. 30 at 8:31 PM
$CCL $LYV $NFLX $BP $JEF Upgrades today in the Buzz https://stocksrunner.com/news/2026-03-30-top-stock-upgrades-today-in-the-buzz
0 · Reply
Redw00d101
Redw00d101 Mar. 30 at 8:04 PM
$JEF don't get stuck in this
0 · Reply
CoolKennedy
CoolKennedy Mar. 30 at 6:47 PM
$JEF what's grooving
0 · Reply
erevnon
erevnon Mar. 26 at 4:00 PM
Goldman Sachs maintains Jefferies Financial $JEF at Buy and lowers the price target from $54 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
briefingcom
briefingcom Mar. 26 at 3:38 PM
$JEF: The transition story is intact, but not clean. Jefferies is gaining traction in investment banking, yet legacy issues continue to weigh on earnings visibility. See the full analysis: https://briefing.com/story-stocks/archive/2026/3/26/jefferies-posts-record-investment-banking-revenue-but-noncash-charges-muddy-profitability-(jef)?utm_campaign=storystocks&utm_medium=social&utm_source=st&utm_content=link $GS $MS #earnings #financialservices #capitalmarkets #investmentbanking
0 · Reply
Knot2
Knot2 Mar. 26 at 2:30 PM
$JEF don’t like the company but like the stock…keep accumulating
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 26 at 12:22 PM
$JEF (+0.6% pre) Jefferies profit rises on dealmaking but misses estimates from losses on First Brands, MFS; declines to comment on reports of Sumitomo considering takeover https://ooc.bz/l/97311
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 26 at 11:15 AM
$JEF Share Price: $39.64 Contract Selected: Jul 17, 2026 $40 Calls Buy Zone: $3.60 – $4.44 Target Zone: $6.27 – $7.66 Potential Upside: 65% ROI Time to Expiration: 112 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 26 at 5:09 AM
you know my style with $JEF patient until H% shows low
0 · Reply
3Henry7
3Henry7 Mar. 26 at 3:24 AM
0 · Reply
_Just_for_fun_
_Just_for_fun_ Mar. 25 at 10:39 PM
$JEF nothing happend here ... im out ... death stock
0 · Reply
Estimize
Estimize Mar. 25 at 10:06 PM
$JEF reported 0.70 EPS and 2,017 revenue for Q1. http://www.estimize.com/intro/jef?chart=historical&metric_name=eps&utm_content=JEF&utm_med
0 · Reply
Finesttrade
Finesttrade Mar. 25 at 9:47 PM
$JEF As expected. Doing down tomorrow. Making money tomorrow.
1 · Reply
mikesterz7
mikesterz7 Mar. 25 at 9:36 PM
$JEF Revenue: $2.02 billion, exceeding the $1.98B–$2.02B consensus. Net Earnings: $155.7 million, a 22% increase from a year earlier. Adjusted EPS: $0.70 (some reports suggest $0.89-$0.90 after specific adjustments). Segment Performance: Investment Banking revenue rose 45% to $1.02 billion; Capital Markets revenue was $779 million, up 12%. Challenges: Results were impacted by a $17 million loss related to credit investments and a $36 million after-tax write-down related to the sale of Tessellis. Outlook & Actions: The firm expanded its share repurchase authorization to $250 million, having already bought back $174 million in Q1.
0 · Reply
Huck18
Huck18 Mar. 25 at 9:11 PM
$JEF Don't Get Caught Short, the Takeover rumor mill is gaining momentum
0 · Reply
Huck18
Huck18 Mar. 25 at 9:08 PM
0 · Reply
Huck18
Huck18 Mar. 25 at 9:07 PM
$JEF Seems Undervalued at this price, shoudl be at least $50
0 · Reply
_Just_for_fun_
_Just_for_fun_ Mar. 25 at 8:53 PM
$JEF earning beat , price not move ... it is normal here ???
1 · Reply